Literature DB >> 11748055

Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids.

Johnson Haynes1, Boniface Obiako.   

Abstract

This study investigates the role of the activated polymorphonuclear cell (APMN) products on sickle red blood cell (SRBC) retention/adherence in the pulmonary circulation. Isolated rat lungs were perfused with (51)Cr-labeled normal RBCs (NRBC) or SRBCs (10% hematocrit) suspensions +/- PMNs. Specific activities of lung and perfusate were measured and retention (the number of SRBC/g lung) was calculated. SRBC retention was 3.5 times greater than NRBC retention. PMN activation was required to increase SRBC retention. Supernatants from APMN increased SRBC retention, which suggested soluble products such as oxidants, PAF, and/or leukotriene (LTB(4)) are involved. Heat inactivation of PMN NADPH oxidase had no effect on retention. Whereas neither platelet-activating factor (PAF) nor LTB(4) (secreted by APMN) increased SRBC retention, PAF+LTB(4) did. The PAF antagonist, WEB-2170, attenuated SRBC retention mediated by PAF+LTB(4) and APMNs. Similarly, zileuton (5-lipoxygenase inhibitor) attenuated APMN-mediated SRBC retention. We conclude the concomitant release of PAF and LTB(4) from APMN is involved in the initiation of microvascular occlusion by SRBCs in the perfused rat lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748055     DOI: 10.1152/ajpheart.2002.282.1.H122

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  7 in total

1.  Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome.

Authors:  Michael Opene; Joseph Kurantsin-Mills; Sumair Husain; Basil O Ibe
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 2.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

3.  Inhibition of myeloperoxidase decreases vascular oxidative stress and increases vasodilatation in sickle cell disease mice.

Authors:  Hao Zhang; Hao Xu; Dorothee Weihrauch; Deron W Jones; Xigang Jing; Yang Shi; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-08-16       Impact factor: 5.922

4.  N-acetyl lysyltyrosylcysteine amide inhibits myeloperoxidase, a novel tripeptide inhibitor.

Authors:  Hao Zhang; Xigang Jing; Yang Shi; Hao Xu; Jianhai Du; Tongju Guan; Dorothee Weihrauch; Deron W Jones; Weiling Wang; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-07-24       Impact factor: 5.922

5.  A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

Authors:  Ted Wun; Denis Soulieres; Andrew L Frelinger; Lakshmanan Krishnamurti; Enrico M Novelli; Abdullah Kutlar; Kenneth I Ataga; Charles L Knupp; Lillian E McMahon; John J Strouse; Chunmei Zhou; Lori E Heath; Chuke E Nwachuku; Joseph A Jakubowski; Jeffrey S Riesmeyer; Kenneth J Winters
Journal:  J Hematol Oncol       Date:  2013-02-17       Impact factor: 17.388

6.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

7.  Increased Vasoocclusive Crises in "O" Blood Group Sickle Cell Disease Patients: Association with Underlying Thrombospondin Levels.

Authors:  M Al Huneini; S Alkindi; V Panjwani; K Al Falahi; B Al Balushi; D Gravell; C H Ho; R Krishnamoorthy; A V Pathare
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-04-20       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.